Drugs / hV01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05914376 | Jul 2023 → Jul 2025 overdue | cancer | Hangzhou Converd Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07006077 | May 2025 → Dec 2028 expected | pancreatic neoplasm | Hangzhou Converd Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07185243 | Jun 2025 → Jun 2027 expected | cancer | Hangzhou Converd Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hV01 | “hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.” NCT07006077 ↗2“hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.” NCT07185243 ↗ “hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.” NCT05914376 ↗ |
| Route | Other | “intratumoral injection” NCT05914376 ↗ |